Co-treatment with troglitazone, TRAIL, and ATG5 siRNA strongly increased cell viability in human lung adenocarcinoma A549 cells with significantly decreased cell death (Figure 5B–5D). Here, ATG5 is linked to lung adenocarcinoma.